Advertisement

Second Opinion in Pharmacotherapy of ADHD: Do Not Postpone It!

  • Jan Schjøtt
    Affiliations
    Regional Medicines Information and Pharmacovigilance Centre (RELIS Vest), and the Department of Clinical Biochemistry and Pharmacology, Haukeland University Hospital; and the Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway
    Search for articles by this author
      Questions posed to drug-information services concerning the treatment of attention-deficit/hyperactivity disorder (ADHD) are not uncommon.
      • Schjøtt J
      • Heitmann K
      • Bakkebø T
      • et al.
      Review of questions concerning clinical drug interactions in ADHD treatment from physicians in Norway.
      At our drug-information service in Norway, we recently received a pertinent question, from a senior consultant from a district psychiatric center, about the optimal number of treatment trials in adult patients with ADHD: “We experience a lot of trial and error which occupies the physician's resources. I am unsure about the utility value for us, and more importantly for the patients. My question for you is, if there is any rationale for trying a fourth or fifth treatment trial when the previous attempts have failed?”.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schjøtt J
        • Heitmann K
        • Bakkebø T
        • et al.
        Review of questions concerning clinical drug interactions in ADHD treatment from physicians in Norway.
        Front Pharmacol. 2020; 11607915
        • Luo Y
        • Weibman D
        • Halperin JM
        • et al.
        A review of heterogeneity in attention deficit/hyperactivity disorder (ADHD).
        Front Hum Neurosci. 2019; 11: 42
        • Katzman MA
        • Bilkey TS
        • Chokka PR
        • et al.
        Adult ADHD and comorbid disorders: clinical implications of a dimensional approach.
        BMC Psychiatry. 2017; 17: 302
        • Schein J
        • Adler LA
        • Childress A
        • et al.
        Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective.
        J Manag Care Spec Pharm. 2022; 28: 168-179
        • Knight A.
        Patient-centred prescribing.
        Australian Prescriber. 2013; 36: 199-201
      1. Attention Deficit Hyperactivity Disorder: Diagnosis and Management [NICE website]. Available at: www.nice.org.uk/guidance/ng87. Accessed February 22, 2022.

        • Heuss SC
        • Schwartz BJ
        • Schneeberger AR.
        Second opinions in psychiatry: a review.
        J Psychiatr Pract. 2018; 24: 434-442
        • Schjøtt J.
        Benefits of a national network of drug information centres: RELIS.
        Eur J Clin Pharmacol. 2017; 73: 125-126
      2. Aiken C. How to Switch Stimulants: A Dosing Guide for ADHD [Psychiat Times online]. Available at: https://www.psychiatrictimes.com/view/how-to-switch-stimulants-dosing-guide-for-adhd. Accessed February 22, 2022.

      3. Dodson W. 11 Steps to Prescribing and Using ADHD Medication Effectively [Attitude Magazine online]. Available at: https://www.additudemag.com/adhd-medication-11-steps-for-prescribing-it-effectively. Accessed February 22, 2022.